Intoplicine dimesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576702

CAS#: 133711-99-6

Description: Intoplicine dimesylate is a DNA topoisomerase I and II inhibitor potentially for the treatment of cancer.

Chemical Structure

img
Intoplicine dimesylate
CAS# 133711-99-6
Instruction

Theoretical Analysis

MedKoo Cat#: 576702
Name: Intoplicine dimesylate
CAS#: 133711-99-6
Chemical Formula: C23H32N4O7S2
Exact Mass: 540.17
Molecular Weight: 540.650
Elemental Analysis: C, 51.10; H, 5.97; N, 10.36; O, 20.71; S, 11.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Intoplicine dimesylate; RP 60475; RP60475; RP-60475

IUPAC/Chemical Name: 11-((3-(dimethylamino)propyl)amino)-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-3-ol dimethanesulfonate

InChi Key: JAUYMMJDKJISLX-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H24N4O.2CH4O3S/c1-13-12-23-21(22-9-4-10-25(2)3)19-18-16-7-6-15(26)11-14(16)5-8-17(18)24-20(13)19;2*1-5(2,3)4/h5-8,11-12,24,26H,4,9-10H2,1-3H3,(H,22,23);2*1H3,(H,2,3,4)

SMILES Code: CN(C)CCCNc1ncc(C)c2[nH]c3ccc4cc(O)ccc4c3c12.CS(=O)(=O)O.CS(=O)(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 540.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767.

2: Etiévant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, Hill BT. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol. 2000;46(2):101-13. PubMed PMID: 10972479.

3: Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs. 1999 Nov;10(10):889-94. PubMed PMID: 10630356.

4: van Gijn R, ten Bokkel Huinink WW, Rodenhuis S, Vermorken JB, van Tellingen O, Rosing H, van Warmerdam LJ, Beijnen JH. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. Anticancer Drugs. 1999 Jan;10(1):17-23. PubMed PMID: 10194543.

5: Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res. 1997 Oct;88(10):992-1002. PubMed PMID: 9414662.

6: Guerquin-Kern JL, Coppey M, Carrez D, Brunet AC, Nguyen CH, Rivalle C, Slodzian G, Croisy A. Complementary advantages of fluorescence and SIMS microscopies in the study of cellular localization of two new antitumor drugs. Microsc Res Tech. 1997 Feb 15;36(4):287-95. PubMed PMID: 9140928.

7: Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 1996 Feb;7(2):166-74. PubMed PMID: 8740721.

8: Hanauske AR, Clark GM, Von Hoff DD. Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Invest New Drugs. 1995;13(1):43-9. PubMed PMID: 7499107.

9: Nabiev I, Chourpa I, Riou JF, Nguyen CH, Lavelle F, Manfait M. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Biochemistry. 1994 Aug 2;33(30):9013-23. PubMed PMID: 8043587.

10: Eckardt JR, Burris HA 3rd, Kuhn JG, Bissery MC, Klink-Alakl M, Clark GM, Von Hoff DD. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1994 Jan 5;86(1):30-3. PubMed PMID: 8271279.

11: Von Hoff DD, Burris HA 3rd, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol. 1994;34 Suppl:S41-5. PubMed PMID: 8070026.

12: Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. New anticancer agents. Cancer Chemother Biol Response Modif. 1994;15:130-51. Review. PubMed PMID: 7779583.

13: Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, Lavelle F. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 1993 Dec 15;53(24):5987-93. PubMed PMID: 8261412.

14: Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. Invest New Drugs. 1993 Nov;11(4):263-77. PubMed PMID: 8157469.

15: van Gijn R, De Graaff-Teulen MJ, van Tellingen O, Beijnen JH. Chemical stability of the new antitumour agent intoplicine in infusion fluids. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1353-6. PubMed PMID: 8123754.

16: van Gijn R, Kuijs S, Rosing H, Dubbelman AC, van Tellingen O, ten Bokkel Huinink WW, Pinedo HM, Beijnen JH. Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1345-8. PubMed PMID: 8123753.

17: Morjani H, Riou JF, Nabiev I, Lavelle F, Manfait M. Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. Cancer Res. 1993 Oct 15;53(20):4784-90. PubMed PMID: 8402662.

18: Poddevin B, Riou JF, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74. PubMed PMID: 8232227.

19: van Gijn R, Rosing H, ten Bokkel Huinink WW, van Tellingen O, Vermorken JB, Liefting AJ, Bruno R, Pinedo HM, Beijnen JH. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1993 May 5;614(2):299-306. PubMed PMID: 8314943.